CPT1A and nonpapillary renal cell carcinoma: CPT1A is the rate-limiting enzyme of mitochondrial β-oxidation, and it has been recognized as a potential therapeutic target for hepatocellular carcinoma (HCC) and ccRCC 3, 14.